In people with hemophilia A, certain immune markers in the blood may help predict patient responses to immune tolerance induction (ITI) — a treatment regimen used for individuals who develop inhibitors after factor replacement therapy — according to a new study by researchers in Brazil. Inhibitors, neutralizing antibodies…
Search results for:
Mobility problems, bleeding, pain, and uncertainly in daily life are the biggest challenges people with hemophilia are facing, according to a survey from six central European countries. Additionally, while most respondents, including caregivers, felt well informed on hemophilia, they continue to seek further education on the condition and new…
The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hympavzi (marstacimab) for the prevention of bleeding episodes in people with both hemophilia A and hemophilia B, ages 12 and older. The therapy, already approved in the U.S. and the European Union, is designed to…
The National Hemophilia Foundation (NHF) is calling for nominations for its Awards of Excellence, which honor members of the bleeding disorders community. The awards are for those who have helped improve the lives of patients with bleeding diseases, including those with hemophilia, through treatment and care, advocacy,…
For years, writing about women with hemophilia and other bleeding disorders has meant telling stories of delayed diagnoses, silent pain, and lives shaped by the absence of care. In many ways, it still does. But lately, I think something has shifted. The change has been gradual, and I don’t…
Every year, the holiday season appears to arrive earlier, a stark contrast to the days when Christmas wasn’t even contemplated until after Thanksgiving. Now, the hustle and bustle of preparations begin as early as Halloween. This year, the approaching holiday season carries a bittersweet weight for me as it’ll be…
When someone we love is diagnosed with a chronic illness, our instincts often compel us to search for solutions: stricter routines, healthier diets, more discipline, or the willpower to push through. While self-help culture tends to praise these strategies, our family’s experience with chronic illness has shown that they can…
Information from patient surveys can help doctors do a better job of managing hemophilia and improving patients’ outcomes, an American study reports. The research, which appeared in the journal Patient Preference and Adherence, was titled “Construct validity of patient-reported outcome instruments in US adults with hemophilia: results from the Pain, Functional…
Treatment for burn injuries is usually straightforward: Cool the skin, manage the wound, control pain, and let time do the rest. That’s the version most people are familiar with. When hemophilia enters the picture, though, even a “simple” burn can quietly turn into something far more complicated. To add…
Beqvez (fidanacogene elaparvovec-dzkt) was a gene therapy that was approved in the U.S. for the treatment of certain adults with moderate to severe hemophilia B. The one-time therapy, given via an into-the-vein or intravenous infusion, was marketed by Pfizer, who made the decision to halt its development and commercialization.